Actively Recruiting
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
Led by Chinese PLA General Hospital · Updated on 2025-04-20
2000
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are examining diabetic nephropathy, a serious complication of diabetes that leads to kidney failure and premature death worldwide. This observational study aims to create a comprehensive life-cycle database by expanding existing large natural population and follow-up cohorts. The goal is to identify risk factors, clinical features, and biomarkers throughout the disease stages and to develop new imaging and assessment methods for microvascular complications involving organs like the kidney and eye. The study follows individuals with type 2 diabetes, tracking their health from diagnosis until kidney dysfunction or renal endpoints occur. Patients with diabetic nephropathy will also be observed until these renal endpoints develop. The project integrates artificial intelligence to analyze diverse medical data and build risk prediction models, while promoting new technologies and medical quality control systems to improve prevention and treatment strategies for diabetic nephropathy. Participants will undergo ongoing evaluations including clinical data collection, imaging, and functional assessments over several years. The primary outcome measured is the incidence of complex renal endpoints within three years. The study supports continuous monitoring with a focus on improving medical care quality, reducing the progression to end-stage kidney disease, and providing long-term services for medical institutions.
CONDITIONS
Brief Title
The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with type 2 diabetes
- History of type 2 diabetes for more than 5 years
- Negative proteinuria (no protein in urine)
- Normal creatinine levels (normal kidney function)
- Good compliance and voluntarily sign informed consent
- For renal biopsy group: kidney damage present (microalbuminuria, dominant albuminuria, or renal insufficiency)
- For renal biopsy group: have undergone renal biopsy with complete pathological diagnosis data
- Voluntarily sign informed consent
You will not qualify if you...
- Incomplete medical records
- Lack of fundus microvascular or new imaging examination results
- Presence of autoimmune diseases or tumors
- Gestational or special type diabetes mellitus
- Patients with hereditary kidney disease
- Missing indicators for comprehensive assessment of renal progression risk
- Pregnancy plans during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 years
Participants with type 2 diabetes are followed over time to observe kidney function and the occurrence of renal endpoints.
Regular follow-up visits depending on participant condition
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853
Actively Recruiting
Research Team
Z
Zheyi Dong, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here